EQS-News: Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG
|
EQS-News: Pentixapharm Holding AG
/ Key word(s): Personnel
Berlin, Germany, March 3, 2025 - Several previously announced personnel changes in the governing bodies of the Pentixapharm Group have taken effect as of March 1, 2025. The Management Board of the parent company Pentixapharm Holding AG is now identical in composition to the Management Board of the wholly owned operational subsidiary Pentixapharm AG. Both companies are now led by Dr. Dirk Pleimes and Henner Kollenberg. Dr. Andreas Eckert, who was temporarily appointed as sole member of the Management Board of the holding company in November 2024 under § 105(2) of the German Stock Corporation Act following the health-related departure of Pentixapharm founder Dr. Hakim Bouterfa, has returned to the Supervisory Board of Pentixapharm Holding AG. He was re-elected as Chairman there. With his return to the Supervisory Board, Dr. Harald Hasselmann's Supervisory Board mandate in Pentixapharm Holding AG has also been reactivated. Hasselmann had suspended his mandate since October due to potential conflicts of interest. Frank Perschmann, who had been acting as Chairman of the Supervisory Board of Pentixapharm Holding AG in recent months, left the board as planned with Eckert's return.
About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds and early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.
Pentixapharm Holding AG
03.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2094397 |
| End of News | EQS News Service |
|
|
2094397 03.03.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 0,00 | 0,07 | 0,06 | 0,05 | 1,77 | 0,12 | 0,00 | |
| EBITDA1,2 | 0,00 | -1,85 | -4,07 | -5,89 | -10,62 | 2,07 | 0,00 | |
| EBITDA-Margin3 | 0,00 | -2.642,86 | -6.783,33 | -11.780,00 | -600,00 | 1.725,00 | 0,00 | |
| EBIT1,4 | 0,00 | -1,92 | -4,18 | -6,00 | -10,76 | -16,97 | 0,00 | |
| EBIT-Margin5 | 0,00 | -2.742,86 | -6.966,67 | -12.000,00 | -607,91 | -14.141,67 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | -1,92 | -4,18 | -1,96 | -7,64 | -12,84 | -18,00 | |
| Net-Margin6 | 0,00 | -2.742,86 | -6.966,67 | -3.920,00 | -431,64 | -10.700,00 | 0,00 | |
| Cashflow1,7 | 0,00 | -1,85 | -2,49 | -2,20 | 2,13 | -4,33 | 0,00 | |
| Earnings per share8 | 0,00 | -0,08 | -0,17 | -0,08 | -0,30 | -0,52 | -0,73 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Pentixapharm Holding | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40AEG | DE000A40AEG0 | AG | 37,09 Mio € | 03.10.2024 | Kaufen | 8FXFRW2H+CF |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -1,00 | 0,00 | 0,00 | -1,66 | 1,01 | -8,57 | 314,36 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 27.05.2025 | 08.05.2025 | 06.08.2025 | 12.11.2025 | 15.04.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -7,60% | -32,22% | -49,29% | -50,79% | -70,67% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
